AstraZeneca Fails to Keep Generic Crestor Rivals Off MarketBy , , and
Company can’t stop copies of its $5 billion cholesterol pill
Federal judge denied request to temporarily block FDA ruling
AstraZeneca Plc can’t stop generic-drug makers from bringing cheaper rivals of its best-selling medicine, the cholesterol fighter Crestor, to the U.S. market.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.